Compare ELPC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELPC | GKOS |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | Brazil | United States |
| Employees | 4276 | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.0B |
| IPO Year | N/A | 2015 |
| Metric | ELPC | GKOS |
|---|---|---|
| Price | $11.76 | $167.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $126.92 |
| AVG Volume (30 Days) | 356.1K | ★ 822.1K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.32 |
| Revenue Next Year | $12.11 | $27.43 |
| P/E Ratio | $77.44 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $7.94 | $73.16 |
| 52 Week High | $13.70 | $184.00 |
| Indicator | ELPC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 72.12 |
| Support Level | $11.33 | $94.16 |
| Resistance Level | $11.83 | N/A |
| Average True Range (ATR) | 0.23 | 7.62 |
| MACD | 0.01 | 0.52 |
| Stochastic Oscillator | 68.98 | 56.01 |
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power Sale, Services, and Holding. The majority of its revenue is generated from the Power distribution segment under which it provides public electricity distribution services, being responsible for the operation and maintenance of the distribution infrastructure, as well as providing related services.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.